文献速递真菌感染

健康志愿者单次和多次静脉输注后艾沙康唑在不同靶部位的药代动力学

Pharmacokinetics of isavuconazole at different target sites in healthy volunteers after single and multiple intravenous infusions.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

一项前瞻性单中心药代动力学研究纳入12名健康志愿者,接受7剂200 mg艾沙康唑静脉输注。假设稳态下血浆Cmax为6.57±1.68 mg/L、AUC0-24h为106±32.1 h·mg/L;脑脊液、上皮衬液和PBMC平均浓度分别为0.07±0.03、0.94±0.46和27.1±17.8 mg/L。艾沙康唑对上皮衬液渗透中等、对脑脊液渗透低、在PBMC中高蓄积,当前给药方案使所有受试者血浆暴露足以治疗MIC≤1 mg/L的分离株。

要点

  • 假设稳态下血浆Cmax为6.57±1.68 mg/L,AUC0-24h为106±32.1 h·mg/L。
  • 脑脊液、上皮衬液和PBMC平均浓度分别为0.07±0.03、0.94±0.46和27.1±17.8 mg/L。
  • 当前给药方案使所有受试者血浆暴露足以治疗MIC≤1 mg/L的分离株。

核心结论

  • 艾沙康唑对上皮衬液渗透中等、对脑脊液渗透低、在PBMC中高蓄积,当前给药方案使所有受试者血浆暴露足以治疗MIC≤1 mg/L的分离株。

研究设计与样本

  • 前瞻性单中心药代动力学研究,纳入12名健康志愿者,接受7剂200 mg艾沙康唑静脉输注以达到假设稳态。
  • 首次和末次输注后分别进行8小时和12小时血浆采样;所有受试者在末次给药后2、6或12小时接受一次腰椎穿刺和支气管肺泡灌洗。
  • 6名受试者采集血PBMC,在6、8或12小时测定细胞内艾沙康唑浓度;以MIC 1 mg/L(EUCAST对烟曲霉和黄曲霉的敏感性折点)计算AUC/MIC。

主要发现

  • 假设稳态下血浆Cmax为6.57±1.68 mg/L(均值±标准差),AUC0-24h为106±32.1 h·mg/L。
  • 脑脊液、上皮衬液和PBMC中平均浓度分别为0.07±0.03、0.94±0.46和27.1±17.8 mg/L。
  • 稳态下血浆、脑脊液、上皮衬液和PBMC的AUC/MIC分别为106±32.1、1.68±0.72、22.6±11.0和650±426 mg·h/L。

关键数值与推荐

  • 以MIC 1 mg/L(EUCAST对烟曲霉和黄曲霉的敏感性折点)计算AUC/MIC。
  • 稳态下血浆AUC/MIC为106±32.1 mg·h/L,脑脊液为1.68±0.72 mg·h/L,上皮衬液为22.6±11.0 mg·h/L,PBMC为650±426 mg·h/L。

临床怎么用

  • 当前给药方案使所有受试者血浆暴露足以治疗MIC≤1 mg/L的分离株。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Invasive aspergillosis is a severe fungal infection that affects multiple organ systems including the CNS and the lungs. Isavuconazole, a novel triazole antifungal agent, has demonstrated promising activity against Aspergillus spp. However, data on the penetration of isavuconazole into the CNS and ELF and intracellular accumulation remain limited. MATERIALS AND METHODS: We conducted a prospective single-centre pharmacokinetic (PK) study in 12 healthy volunteers. Subjects received seven doses of 200 mg isavuconazole to achieve an assumed steady-state. After the first and final infusion, plasma sampling was conducted over 8 and 12 h, respectively. All subjects underwent one lumbar puncture and bronchoalveolar lavage, at either 2, 6 or 12 h post-infusion of the final dose. PBMCs were collected in six subjects from blood to determine intracellular isavuconazole concentrations at 6, 8 or 12 h. The AUC/MIC was calculated for an MIC value of 1 mg/L, which marks the EUCAST susceptibility breakpoint for Aspergillus fumigatus and Aspergillus flavus. RESULTS: C max and AUC0-24h of isavuconazole in plasma under assumed steady-state conditions were 6.57 ± 1.68 mg/L (mean ± SD) and 106 ± 32.1 h·mg/L, respectively. The average concentrations measured in CSF, ELF and in PBMCs were 0.07 ± 0.03, 0.94 ± 0.46 and 27.1 ± 17.8 mg/L, respectively. The AUC/MIC in plasma, CSF, ELF and in PBMCs under steady-state conditions were 106 ± 32.1, 1.68 ± 0.72, 22.6 ± 11.0 and 650 ± 426 mg·h/L, respectively. CONCLUSION: Isavuconazole demonstrated moderate penetration into ELF, low penetrability into CSF and high accumulation in PBMCs. Current dosing regimens resulted in sufficient plasma exposure in all subjects to treat isolates with MICs ≤ 1 mg/L.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Bergmann F, Wölfl-Duchek M, Jorda A, et al. Pharmacokinetics of isavuconazole at different target sites in healthy volunteers after single and multiple intravenous infusions. J Antimicrob Chemother. 2024. PMID: 38546795. doi:10.1093/jac/dkae088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。